Journal article
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, M Singh, CS Karapetis, J Desai, B Tran, RL Strausberg, LA Diaz, N Papadopoulos, KW Kinzler, B Vogelstein, P Gibbs
Annals of Oncology | Published : 2015
Abstract
Background: Early indicators of treatment response in metastatic colorectal cancer (mCRC) could conceivably be used to optimize treatment. We explored early changes in circulating tumor DNA (ctDNA) levels as a marker of therapeutic efficacy. Patients and methods: This prospective study involved 53 mCRC patients receiving standard first-line chemotherapy. Both ctDNA and CEA were assessed in plasma collected before treatment, 3 days after treatment and before cycle 2. Computed tomography (CT) scans were carried out at baseline and 8-10 weeks and were centrally assessed using RECIST v1.1 criteria. Tumors were sequenced using a panel of 15 genes frequently mutated in mCRC to identify candidate m..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by Victorian Cancer Agency Translational Research Grant; Hilton Ludwig Cancer Prevention Initiative funded by the Conrad N. Hilton Foundation and the Ludwig Institute for Cancer Research; National Institutes of Health (grant numbers CA152753, CA57345 and CA62924); and Victorian Cancer Agency Clinical Research Fellowship (to JT).